Safran H, Rathore R. Paclitaxel as a radiation sensitizer for locally advanced pancreatic cancer. Crit Rev Oncol Hematol 2002;43:57- 62.Safran H, Rathore R. Paclitaxel as a radiation sensitizer for locally advanced pancreatic cancer. Critical reviews in oncology/hematology. 2002;43(1):57-62....
Century Oncology, University of Florida Health Oncology, Jacksonville, FL, USA Background: Nanoparticle albumin-bound paclitaxel (nab-P) plus gemcitabine (Gem) became a standard treatment option for metastatic pancreatic cancer (MPC) following positive results from a global phase III trial (MPACT). ...
Nab-paclitaxel (nab-P) combined with FOLFOX for advanced pancreatic cancer: A phase I study The contribution of irinotecan to the efficacy of FOLFIRINOX in pancreatic cancer is uncertain. The addition of irinotecan to gemcitabine was not superior to gemcitabine alone in pancreatic cancer, however ...
While the combination of gemcitabine and nab-paclitaxel (Abraxane) has demonstrated survival benefits for patients with metastatic pancreatic cancer, oncologists are interested in knowing whether the regimen will transfer well into the adjuvant setting, according to experts who participated in an OncLive ...
Background/objectivesThe incidence of pancreatic cancer is increasing in developed countries. The incorporation of new therapies, to the first-line treatment of patients with good performance status led to better survival in clinical trials. However, there is a wide variability in their use and some...
Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. OncoTargets and therapy. 2014; 7 :187–192.Al-Hajeili M, Azmi AS, and Choi... C Minsig,AH Marwan,A Asfar - 《Oncotargets & Therapy》 被引量: 38发表: 2014年 A phase II trial of nab-paclitaxel (NP) in patien...
The FDA has granted orphan drug designation for paclitaxel albumin-bound particles for injectable suspension in the treatment of pancreatic cancer and stage IIB to IV melanoma.
Pancreatic cancer (PDAC) is an aggressive and chemoresistant disease, representing the fourth cause of cancer related deaths in western countries. Majority of patients have unresectable, locally advanced or metastatic disease at time of diagnosis and the 5-year survival rate in these conditions is ex...
Pancreatic cancer (PDAC) is an aggressive and chemoresistant disease, representing the fourth cause of cancer related deaths in western countries. Majority of patients have unresectable, locally advanced or metastatic disease at time of diagnosis and the 5-year survival rate in these conditions is ex...
Objective response rate of GEM plus nab-paclitaxel (44.8%) was higher than conventional regimens for LAPC (5–41%) (Table3). These results are consistent with those of the phase I/II study of GEM plus nab-paclitaxel for metastatic pancreatic cancer reported by Uenoet al. The authors showed...